Theravance Biopharma (NASDAQ: TBPH) reported Q4 EPS of ($0.31), $0.11 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $18.8 million versus the consensus estimate of $16.6 million.

2025 Financial Guidance

Operating Expenses (excluding share-based compensation): The Company expects full year 2025 R&D expense of $32 million to $38 million and SG&A expense of $50 million to $60 million, in each case excluding share-based compensation.

Share-Based Compensation: The Company expects full year share-based compensation expense of $18 million to $20 million.

Non-GAAP Loss from Operations and Cash Burn6: The Company expects minimal levels of Non-GAAP Losses from Operations and Cash Burn in 2025, similar to levels incurred in 2024.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.